Dow, S&P 500, Nasdaq futures falter as Trump Greenland drama marks latest volatile week

🏭 Apple supplier Pegatron expects US plant to be completed by end-March

Taiwanese contract electronics manufacturer Pegatron’s first US factory, located in Texas, is expected to be completed by the end of March, with trial production set to begin around then or in April, according to President and CEO Kuang-Chih Cheng.

The company, which supplies Apple, Microsoft, and Tesla, said in October it had acquired an industrial building and land in Texas, joining other Taiwanese technology manufacturers investing in the state, including Foxconn, Inventec, and Wistron.

“The US plant is our first factory established and operated in the United States,” Cheng told reporters in Taipei.

The factory will produce AI server products, including those using Nvidia chips. Yahoo Finance reports.


✈️ GE Aerospace stock steadies premarket after 7% earnings drop as airlines push back on engine costs

GE Aerospace shares ticked higher in early trading Friday, rebounding slightly after a steep drop the day before.

The jet-engine maker’s stock rose 0.8% to $297.40 by 5:00 a.m. EST, following a 7.4% slide that pushed it down to $295 on Thursday.

Investors are parsing GE’s 2026 forecast, which leans heavily on robust performance in its aftermarket segment, the parts and repair work that kicks in once engines are operational.

The company projects adjusted earnings of $7.10 to $7.40 per share for 2026, edging just above the $7.11 analyst consensus tracked by LSEG. It also expects low double-digit growth in adjusted revenue. TechStock² reports.


📱 Meta stock steadies before the bell after a 5.7% pop, here’s what’s driving now

Meta Platforms shares slipped roughly 0.1% in premarket trading Friday, following a 5.7% rally the day before.

That surge shifted attention to fresh ad inventory and how much Wall Street is willing to tolerate when it comes to the company’s AI spending.

Timing is crucial. Meta is set to release its results next week, and traders are weighing whether new revenue drivers such as Threads, WhatsApp, and AI ad tools can keep pace with rising costs.

The question becomes sharper as large technology companies head into a busy earnings season, with market gains increasingly dependent on just a handful of names. TechStock² reports.


🧠 Applied Materials stock could have further to run according to latest upgrade

Applied Materials stock has had a strong start to 2026, rising 18.56% year to date with fewer than three weeks of trading completed.

There could be further upside ahead, according to a notable upgrade from Deutsche Bank, which lifted its rating to buy from hold and raised its price target to $390 from $275.

Deutsche Bank’s bullish stance reflects a “much more constructive” outlook for the wafer fabrication equipment market heading into 2026 and 2027.

The firm has revised its estimates higher, placing them about 10% above Street consensus, with potential for additional upside risk. AskTraders reports.


🛢️ SLB stock hits new 52-week high ahead of earnings: what to expect

Schlumberger’s stock heads into this morning’s earnings on the back of fresh highs, trading at $49.69 in premarket action ahead of the report.

SLB is scheduled to release its earnings before the opening bell, with markets expecting earnings per share of $0.74 on revenue of $9.55 billion.

These figures would reflect a 2.82% year-over-year sales growth rate, but a decline in earnings per share from the $0.92 reported this time last year.

Having gained 22.69% since the start of the year, the current share price sits comfortably above both the 50-day simple moving average of $39.17 and the 200-day simple moving average of $35.75.

This technical positioning points to a bullish trend, indicating sustained positive momentum in the stock’s performance. AskTraders reports.


🧬 Why did Revelation Biosciences stock jump over 25% after-hours?

Revelation Biosciences surged 25.22% in after-hours trading to $1.07 on Thursday after the company announced it reached an agreement with the Food and Drug Administration on an approval pathway for its proprietary drug candidate Gemini as a treatment for acute kidney injury.

The stock closed Thursday at $0.85, up 1.71%, according to Benzinga Pro data.

The FDA agreed on two key points: a composite endpoint of death and or the need for dialysis, and that positive results from a single Phase 2/3 adaptive study involving about 300 patients would be sufficient for a new drug application submission. Benzinga reports.

*Estimate and Actual numbers represent Earnings Per Share in US Dollars


ERIC: Telefonaktiebolaget L M
Q4 2025
Before Market Open
Estimate: 0.230
Actual: 0.273

SLB: SLB
Q4 2025
Before Market Open
Estimate: 0.740
Actual: N/A

BAH: Booz Allen Hamilton
Q3 2026
Before Market Open
Estimate: 1.270
Actual: N/A

Time (ET) / Report / Period

10:00 AM - Consumer sentiment (final) - Jan.
9:45 AM - S&P flash U.S. services PMI - Jan.
9:45 AM - S&P flash U.S. manufacturing PMI - Jan.

“The essence of investment is management of risk, not management of returns.”

– Benjamin Graham

Sourced in: Benjamin Graham Quotes – GuruFocus.

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.